Fortrea Holdings Inc. (FTRE) · Oct 29, 2026 · Earnings
Beat — Adjusted diluted EPS $0.28 vs ~$0.22 consensus
Fortrea earnings beat on adjusted EPS and revenue, with 2026 guidance raised. The catch: a $558M backlog reset exposes weaker contract quality.
Fortrea is a contract research organization trying to return to growth through better commercial execution, operational efficiency, early-clinical capabilities and technology investment. Its prior quarter already showed improving bookings and raised 2026 guidance, so this report was primarily a test of whether that improvement was converting into earnings and cash.
The quarter beat a lowered market bar. Revenue was $691.5 million, ahead of the published consensus of roughly $671.6 million, while adjusted diluted EPS was $0.28 versus about $0.22 expected. Adjusted EBITDA rose to $58.0 million from $50.7 million a year earlier, and operating cash flow reached $60.8 million for the quarter. The business is still not growing at the top line—revenue declined 1.4% year over year—but margins and cash generation improved enough to make the quarter better than expectations. The company said, “Third quarter adjusted net income was $27.9million and adjusted diluted EPS was $0.28.”
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Statements) | $691.5M (-1.4%) | $701.3M | $671.6M |
| Adjusted diluted EPS (Adjusted Net Income) | $0.28 (+133%) | $0.12 | ~$0.22 |
| Adjusted EBITDA (Adjusted EBITDA) | $58.0M (+14.4%) | $50.7M | |
| Free cash flow (Free Cash Flow) | $52.5M | ||
| FY revenue guidance (Guidance) | $2,665M-$2,690M | $2,620M-$2,690M prior | |
| FY adjusted EBITDA guidance (Guidance) | $210M-$218M | $205M-$220M prior |
Guidance moved up, but the raise is incremental rather than transformational. Fortrea lifted the midpoint of revenue guidance by about $22.5 million and adjusted EBITDA guidance by about $1.5 million while narrowing both ranges. That supports the return-to-growth narrative and confirms management is seeing enough execution improvement to raise its floor, but the upper ends did not move for revenue and actually fell for EBITDA. The company said it was “narrowing the revenue and adjusted EBITDA ranges and raising both midpoints.” 〔0〕
The backlog reset is the report’s important complication. Fortrea removed $558 million from reported backlog after reviewing contract scope, delivery requirements and inactive trials, leaving adjusted backlog at $7.316 billion. Management says the change does not affect historical results, current guidance or near-term revenue, and the 1.12x book-to-bill ratio was unchanged. Even so, the adjustment reduces confidence in backlog as a clean measure of future revenue and shows that some previously reported work was less executable than the headline number implied. The filing says, “the Company reduced backlog by $558million to reflect the cumulative impact of estimated scope and study delivery requirements across customer contracts, including inactive trials.”
Cash conversion improved materially. Nine-month operating cash flow reached $72.7 million versus a $15.6 million use a year earlier, while cash increased to $220.6 million from $174.6 million at year-end. That gives Fortrea more room to fund its early-clinical and technology investments, although total debt remained about $1.06 billion and the company remained loss-making on a nine-month GAAP basis. The cash-flow statement reports “Net cash provided by (used for) operating activities72.7(15.6).”
Bottom line: Fortrea delivered a genuine earnings and guidance beat, showing that its operational recovery is producing better profit and cash. But the $558 million backlog haircut keeps the broader growth story from being clean: execution improved, while the quality of the order book needed a reset.
Q4 results and FY 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!